Abstract

BIOACTIVITY OF RECOMBINANT HUMAN INSULIN PRODUCED BY PICHIA PASTORIS

Rafid abdulwahid, Dr. Subhi. Jawad *

Abstract

Background: Recombinant DNA technology has made a revolutionary impact in the area of human healthcare by enabling mass production of safe, pure and effective rDNA expression products, currently several categories of rDNA products like hormones of therapeutic interest, haemopoietic growth factors, blood coagulation products, thrombolytic agents, anticoagulants, interferons, interleukins and therapeutic enzymes are being produced using recombinant DNA technology for human use. MATERIALS AND METHODS: Production of human insulin was perfumed by standard methods total RNA was isolated from pancreatic tissue, then RNA was converted to cDNA using RT-P RCR reaction and preproinsulin gene was inserted into the pPIC9K to produce the expression plasmid named pPIC9K-hpi expression vector. Which then transferred to Pichiapastorisby electroporation method. four groups of diabetic rats were used in this study according to protocol used by animal models of diabetic complications consortium (AMDCC) members to induce type 1diabetes in a number of the animal models developed by the consortium (AMDCC, 2013). Plasma glucose levels of all four groups were measured before and after experimentation.

Keywords: recombinant human insulin,pichiapastoris, antidiabetic activity, glucose levels.